Nativity scene hearing delayed to Monday *update*

first_imgLocal courthouse nativity display at center of First Amendment debate.Update (December 19 @ 6 p.m.)The Franklin County Nativity scene will remain in place for Christmas.Read more here. Update (December 19 @ 12:10 p.m.)A continuance has been ordered and the hearing has been rescheduled for 11:00 a.m. Monday, December 22.First Report (December 18 @ 10 p.m.)INDIANAPOLIS – An injunction hearing scheduled for Friday will decide whether the Franklin County Courthouse Nativity scene is on display during the holidays.The U.S. District Court for the Southern District of Indiana hearing is in regards to a Freedom from Religion Foundation (FFRF) request to have the display temporarily taken down until legal proceedings are resolved.Franklin County commissioners Tom Linkel and Tom Wilson will attend the hearing alongside county attorney John Worth and two attorneys from Chicago.The ACLU of Indiana filed a case Tuesday on behalf of the FFRF and two Franklin County residents alleging the Nativity’s location is a violation of the First Amendment.last_img read more

Gabriela Knutson earns 1st team All-ACC honors, Miranda Ramirez named to 3rd team

first_img Facebook Twitter Google+ Published on April 25, 2019 at 5:35 pm Contact Andrew: | @CraneAndrew For the second consecutive season, No. 13 Gabriela Knutson was named first-team All-ACC. The senior has gone 16-8 in singles and 13-10 in doubles for the Orange this season, and moved into second place for all-time SU career wins after a straight-set singles win against Harvard on Feb. 17. Knutson is the first SU player to make the All-ACC first team twice since the Orange switched from the Big East to ACC in 2014.Additionally, junior Miranda Ramirez earned third-team All-ACC honors. She’s currently ranked No. 97 with a 17-7 singles record — primarily at second singles — and a 13-10 doubles record with Knutson. Last season, Ramirez received second-team honor after she went 11-12 in singles and climbed to No. 8 in the doubles rankings with Knutson.Miami junior Estela Perez-Somarriba was named ACC Player of the Year for the second consecutive season behind a 22-1 singles record that propelled her to No. 2 in the most recent ITA rankings. Knutson lost to Perez-Somarriba 7-6, 7-6 in the Orange’s 5-2 loss to the Hurricanes on April 7.No. 31 Syracuse (13-12, 5-9 Atlantic Coast) will find out its opponent for the NCAA tournament during next Monday’s selection show at 6:30 p.m. The Orange dropped their last match 4-0 to UNC in the ACC tournament quarterfinals.AdvertisementThis is placeholder text Commentslast_img read more

Swisscoms TV subscriber base grew by 109 last y

first_imgSwisscom’s TV subscriber base grew by 10.9% last year to take the Swiss telco’s total TV base to 1.48 million, a year-on-year increase of 145,000 homes.According to the telco, the numbers give it a market share of 32%, up from 29% at the end of 2015, despite stiff competition from cable. By comparison, Liberty Global’s UPC Cablecom had a 27% market share, made up of 579,000 basic customers and 656,000 premium customers.The number of Swisscom TV additions was down slightly on the previous year’s total of 166,000 net adds, which the company said was due to saturation of the market. Q4 net adds for TV numbered 36,000, down slightly on the Q3 figure of 40,000.TV and broadband adds have failed to wholly compensate for lost fixed voice, although the telco slowed the rate of voice decline in 2016.Swisscom’s ‘TV Light’ basic offering had 301,000 customers at the end of the year, while its pay TV offering had 1.175 million customers.Swisscom said that practically all new fixed-line customers were taking TV as part of a bundled offering. By the end of 2016, the number of customers using bundled packages had increased year-on-year by 256,000 or 18.1% to 1.67 million. Revenue from bundled contracts increased by CHF268 million (€252 million) or 12.0% to CHF2.5 billion.Overall, 94% of TV customers took the service as part of a bundle, compared with 85% of broadband customers.Swisscom said that it planned to transition all its services – including telephony, TV and data to IP by the end of this year.Overall, Swisscom posted revenues of CHF11.64 billion, flat year-on-year, although revenue from its core Swiss business dropped by 1.1% to CHF9.44 billion.EBITDA grew by 4.8% to CHF4.29 billion. However adjusted EBITDA fell by 1.2%.“We have lived up to our promise and achieved the forecast for 2016. It was certainly hard going and the pressure on prices and the reduction in roaming fees presented us with a real challenge. But we worked on cutting our costs and performed well on the market. I am especially pleased with innovations such as the data transmission standard, the further development of our TV offering and the progress we have made in the corporate business. I was also impressed by the market performance of Fastweb in Italy. In future we will do our utmost to ensure Swisscom’s entrepreneurial freedom and ability to invest and innovate in an extremely competitive market,” said CEO Urs Schaeppi.last_img read more

2PG Company receives grant to develop sensitive lowcost molecular diagnostic tests for

first_img Source: Reviewed by Alina Shrourou, B.Sc. (Editor)Nov 19 2018Two Pore Guys, Inc. (2PG) today announced that the company has received a $2.8 million grant from the Bill & Melinda Gates Foundation to develop sensitive, low-cost molecular diagnostic tests for tuberculosis (TB) using its solid-state nanopore technology. The 18-month grant will fund proof-of-concept work to determine if 2PG technology could provide an easy-to-use, sensitive and low-cost point-of-care device that would be compatible with automated, wireless reporting for resource-poor settings.TB is one of the top 10 causes of death worldwide, and the leading cause from a single infectious agent. Millions of people continue to fall sick with TB each year. WHO estimates 10 million people developed TB last year worldwide.Related StoriesECDC-WHO report: TB remains a major public health challenge in the European regionHIV patients diagnosed with tuberculosis more likely to die within 10 years, study findsScientists discover hundreds of protein-pairs through coevolution studyThe WHO 2018 Global TB Report, released in September, calls for an unprecedented mobilization of national and international commitments to meet the global target of ending TB by 2030. Underdiagnosis of TB is a major challenge: only about 6.4 million of the 10 million people who contracted TB in 2017 were officially recorded by national reporting systems, leaving 3.6 million people undiagnosed or detected but not reported. Late detection of Mycobacterium tuberculosis (MTB), the infectious organism that causes TB, increases the risk of transmission, delays treatment, and burdens the healthcare system. Lack of affordable, sensitive and rapid detection of MTB is a major hurdle in low- and middle-income countries. Implementing a low-cost, sensitive and portable molecular diagnostic test is expected to save thousands of dollars per patient.”Our point-of-care technology platform offers tremendous value to address medical testing needs in resource-limited areas,” said William Dunbar, Co-founder and interim CEO of Two Pore Guys. “We are grateful to the Bill & Melinda Gates Foundation for this support and for their enthusiasm about the promise of our technology. We hope to make a difference in the lives of millions of people around the world who need better access to affordable TB care.”last_img read more

Asuragen launches assay to help diagnose Steinerts Disease

first_imgReviewed by Alina Shrourou, B.Sc. (Editor)Dec 4 2018Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced the CE marking and launch of the AmplideX® DM1 Dx Kit, which simplifies the analysis of repeat expansions within the DMPK gene and is intended to aid in the diagnosis of Myotonic Dystrophy Type I (DM1), also known as Steinert’s Disease.DM1 is an inherited form of muscular dystrophy that affects approximately 1 in 8,000 people worldwide. The condition is associated with a repeat expansion of 50 CTG trinucleotides or greater in the DMPK gene, with disease severity positively correlated to the number of repeats. These expansions can extend beyond a thousand repeats, requiring the use of cumbersome Southern blot technology to estimate their size and assess disease prognosis.Related StoriesScientists develop universal FACS-based approach to heterogenous cell sorting, propelling organoid researchNew natural product fractions library to advance drug discovery effortsPipettes of the Future: Automation for Acceleration”We have verified the [AmplideX DM1 Dx Kit] in our diagnostic laboratory and were delighted with the results,” said Nicola Williams, consultant clinical scientist of Queen Elizabeth University Hospital in Glasgow. “This assay is easy to use from test setup to analysis and reporting of results. It was able to detect and resolve every expansion we investigated and provided accurate sizing of large pathogenic repeats.”The AmplideX DM1 Dx Kit provides multiple benefits to laboratories analyzing this challenging target. The assay features a streamlined, PCR-only workflow with the ability to detect and size repeat expansions up to 200 repeats within an eight-hour laboratory shift. For larger expansions up to 1000 repeats, the assay also features an optional agarose gel electrophoresis (AGE) workflow to further estimate their size without the requirement for Southern blot. The kit provides all necessary reagents to accurately size these expansions from as little as 20 ng DNA. Powered by Asuragen’s proprietary AmplideX technology, the assay’s unique, three-primer design also helps to resolve zygosity and detect low-level mosaicism in patient samples. As with the broader AmplideX portfolio of products, the assay is indicated for use on the established suite of Applied Biosystems™ Genetic Analyzers, including the 3130, 3500, and 3730 platforms.”Despite recent technical advances within our industry, the detection and sizing of repeats in DMPK has remained a significant challenge for diagnostic laboratories worldwide,” said Matthew McManus, M.D., Ph.D., president and CEO of Asuragen. “With this launch, we continue to demonstrate that AmplideX technology is a powerful clinical tool with benefits not just for laboratorians, but also the clinicians and patients who depend on their results.”​ Source: read more